• Search
  • Advanced Search

Current issue

  • HOME
  • BROWSE ARTICLES
  • Current issue
Volume 31(1); Jan 2025
Review
2048
Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.   Published online October 2, 2024
2050
Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho
Clin Mol Hepatol. 2025;31(1):32-55.   Published online October 2, 2024
2073
Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
Clin Mol Hepatol. 2025;31(1):56-73.   Published online October 21, 2024
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
Clin Mol Hepatol. 2025;31(1):74-89.   Published online October 23, 2024
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Atsumasa Komori, Yuki Kugiyama
Clin Mol Hepatol. 2025;31(1):90-104.   Published online November 11, 2024
Original Article
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi
Clin Mol Hepatol. 2025;31(1):105-118.   Published online July 11, 2024
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park
Clin Mol Hepatol. 2025;31(1):119-130.   Published online September 24, 2024
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi
Clin Mol Hepatol. 2025;31(1):131-146.   Published online October 2, 2024
USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li
Clin Mol Hepatol. 2025;31(1):147-165.   Published online October 2, 2024
Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
Clin Mol Hepatol. 2025;31(1):166-178.   Published online October 4, 2024
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian
Clin Mol Hepatol. 2025;31(1):179-195.   Published online October 11, 2024
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing
Clin Mol Hepatol. 2025;31(1):196-212.   Published online October 15, 2024
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin
Clin Mol Hepatol. 2025;31(1):213-226.   Published online October 17, 2024
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(1):227-239.   Published online November 14, 2024
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy
Clin Mol Hepatol. 2025;31(1):240-255.   Published online November 21, 2024
Editorial
Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip
Clin Mol Hepatol. 2025;31(1):256-260.   Published online September 3, 2024
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis”
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2025;31(1):261-263.   Published online September 20, 2024
Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
Yangyue Zhang, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2025;31(1):264-267.   Published online September 20, 2024
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clin Mol Hepatol. 2025;31(1):268-274.   Published online September 24, 2024
Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis”
Kyung-Ah Kim
Clin Mol Hepatol. 2025;31(1):275-276.   Published online October 8, 2024
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
Won Sohn
Clin Mol Hepatol. 2025;31(1):277-280.   Published online October 11, 2024
UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma: Editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
Martina Mang Leng Lei, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(1):281-285.   Published online July 23, 2024
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023”
Ilona Argirion
Clin Mol Hepatol. 2025;31(1):286-289.   Published online August 5, 2024
MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
Rex Wan-Hin Hui, Lung-Yi Mak
Clin Mol Hepatol. 2025;31(1):290-292.   Published online August 7, 2024
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Andrea Caddeo, Rosellina M. Mancina
Clin Mol Hepatol. 2025;31(1):293-296.   Published online August 27, 2024
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
Johanna K. DiStefano, Glenn S. Gerhard
Clin Mol Hepatol. 2025;31(1):297-300.   Published online August 27, 2024
Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Soon Kyu Lee, Jong Young Choi
Clin Mol Hepatol. 2025;31(1):301-303.   Published online August 30, 2024
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
Rainbow Wing Hei Leung, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(1):304-307.   Published online August 30, 2024
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Hiroaki Kanzaki, Yujin Hoshida
Clin Mol Hepatol. 2025;31(1):308-310.   Published online August 30, 2024
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Naoshi Nishida
Clin Mol Hepatol. 2025;31(1):311-315.   Published online September 3, 2024
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”
Soon Sun Kim, Jae Youn Cheong
Clin Mol Hepatol. 2025;31(1):316-318.   Published online October 7, 2024
Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”
Yang-Hyun Baek
Clin Mol Hepatol. 2025;31(1):319-322.   Published online October 7, 2024
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
Sergi Marco, Chiara Braconi
Clin Mol Hepatol. 2025;31(1):323-326.   Published online October 29, 2024
Snapshot
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
Clara Meda, Arianna Dolce, Sara Della Torre
Clin Mol Hepatol. 2025;31(1):327-332.   Published online August 5, 2024
Letter to the Editor
Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
Jiawen Wang, Tian Xia
Clin Mol Hepatol. 2025;31(1):e1-e2.   Published online September 26, 2024
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
Clin Mol Hepatol. 2025;31(1):e3-e4.   Published online October 7, 2024
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
Donghee Kim, Won Kim, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(1):e5-e7.   Published online October 8, 2024
Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
Zhanna Zhang, Gongqiang Wu
Clin Mol Hepatol. 2025;31(1):e8-e9.   Published online November 6, 2024
Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu
Clin Mol Hepatol. 2025;31(1):e10-e12.   Published online November 26, 2024
Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e13-e14.   Published online September 2, 2024
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Xiao-Song Li, Xi-Ping Shen, Hang Li
Clin Mol Hepatol. 2025;31(1):e15-e16.   Published online September 12, 2024
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
Xiping Shen, Ji Wu
Clin Mol Hepatol. 2025;31(1):e17-e18.   Published online October 11, 2024
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e19-e20.   Published online October 17, 2024
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
Wei Feng, Qile Wang, Qingwang Ye
Clin Mol Hepatol. 2025;31(1):e21-e22.   Published online October 11, 2024
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
Clin Mol Hepatol. 2025;31(1):e23-e24.   Published online November 26, 2024
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
Clin Mol Hepatol. 2025;31(1):e25-e26.   Published online December 10, 2024
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang
Clin Mol Hepatol. 2025;31(1):e27-e30.   Published online August 7, 2024
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
Clin Mol Hepatol. 2025;31(1):e31-e34.   Published online September 20, 2024
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China
Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
Clin Mol Hepatol. 2025;31(1):e39-e43.   Published online October 23, 2024
Correspondence
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
Clin Mol Hepatol. 2025;31(1):e44-e47.   Published online October 21, 2024
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e48-e51.   Published online September 11, 2024
Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol. 2025;31(1):e52-e54.   Published online September 24, 2024
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Young-Joo Jin, Seung Up Kim
Clin Mol Hepatol. 2025;31(1):e55-e57.   Published online October 7, 2024
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian
Clin Mol Hepatol. 2025;31(1):e58-e60.   Published online July 29, 2024
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol. 2025;31(1):e61-e63.   Published online October 15, 2024
Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
Clin Mol Hepatol. 2025;31(1):e64-e66.   Published online August 19, 2024
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clin Mol Hepatol. 2025;31(1):e67-e69.   Published online September 10, 2024
Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
Clin Mol Hepatol. 2025;31(1):e70-e73.   Published online September 10, 2024
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Satya Priya Sharma, Ki Tae Suk
Clin Mol Hepatol. 2025;31(1):e74-e77.   Published online October 15, 2024
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
Sang Bae Lee, KyeongJin Kim
Clin Mol Hepatol. 2025;31(1):e78-e80.   Published online September 10, 2024
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e81-e83.   Published online October 7, 2024
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e84-e86.   Published online October 7, 2024
Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK”
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol. 2025;31(1):e87-e89.   Published online October 29, 2024
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
Yu-Hang Ye, Shao-Lai Zhou
Clin Mol Hepatol. 2025;31(1):e90-e92.   Published online November 11, 2024
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
Moon Haeng Hur, Yoon Jun Kim
Clin Mol Hepatol. 2025;31(1):e93-e95.   Published online November 6, 2024
Correspondence to letter to the editor 1 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e96-e97.   Published online November 11, 2024
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2025;31(1):e98-e100.   Published online October 21, 2024
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e101-e102.   Published online November 6, 2024
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Yuri Cho, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e103-e104.   Published online September 24, 2024
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e105-e107.   Published online November 4, 2024
Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
Clin Mol Hepatol. 2025;31(1):e108-e109.   Published online August 5, 2024
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e110-e112.   Published online October 2, 2024
Reply to Correspondence
Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Antonio Bertoletti, Anthony T Tan
Clin Mol Hepatol. 2025;31(1):e113-e116.   Published online October 11, 2024
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clin Mol Hepatol. 2025;31(1):e117-e118.   Published online November 11, 2024
Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”
Martina Mang Leng Lei, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(1):e119-e120.   Published online August 5, 2024
Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Hiroaki Kanzaki, Yujin Hoshida
Clin Mol Hepatol. 2025;31(1):e121-e122.   Published online October 11, 2024
Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”
Yang-Hyun Baek
Clin Mol Hepatol. 2025;31(1):e123-e124.   Published online November 6, 2024

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 3314
TOTAL : 2372090
Close layer